Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Revenue (2016 - 2025)

Anaptysbio's Revenue history spans 10 years, with the latest figure at $75.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 200.0% year-over-year to $75.0 million; the TTM value through Dec 2025 reached $175.0 million, up 201.0%, while the annual FY2025 figure was $234.6 million, 157.01% up from the prior year.
  • Revenue reached $75.0 million in Q4 2025 per ANAB's latest filing, up from $50.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $75.0 million in Q4 2025 to a low of $970000.0 in Q1 2022.
  • Average Revenue over 5 years is $15.5 million, with a median of $9.5 million recorded in 2021.
  • Peak YoY movement for Revenue: tumbled 98.32% in 2021, then soared 422.49% in 2024.
  • A 5-year view of Revenue shows it stood at $1.0 million in 2021, then surged by 394.56% to $5.0 million in 2022, then surged by 80.1% to $9.0 million in 2023, then soared by 177.62% to $25.0 million in 2024, then skyrocketed by 200.0% to $75.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Revenue are $75.0 million (Q4 2025), $50.0 million (Q3 2025), and $22.3 million (Q2 2025).